
CLAIMS



1. Use of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, in the preparation of a medicament for ameliorating or treating a viral infection, wherein the compound of Formula (I) has the structure:



(I)

wherein:

B^{1A} is




 or , wherein R^{G2} is an unsubstituted C_{1-6} alkyl;

R^{3A} is halo, OH, –OC(=O)R"^{A} or an unsubstituted O-linked α-amino acid;

R^{4A} is OH or halo;


R^{a1} and R^{a2} are independently hydrogen or deuterium;


R^{A} is hydrogen or deuterium;

R^{1A} is selected from the group consisting of hydrogen ,  and ;

R^{2A} is halo or $–(CH_2)_{1-6}$halogen;

R^{5A} is selected from the group consisting of an unsubstituted C_{1-6} alkyl, an unsubstituted C_{2-6} alkenyl and an unsubstituted C_{2-6} alkynyl;

R^{6A} and R^{7A} are independently selected from the group consisting of absent, hydrogen and  ; or

R^{6A} is  and R^{7A} is absent or hydrogen;

R^{8A} is absent, hydrogen, an optionally substituted phenyl or an optionally substituted naphthyl;

R^{9A} is an optionally substituted N-linked α-amino acid selected from the group consisting of N-linked alanine, N-linked asparagine, N-linked aspartate, N-linked cysteine, N-linked glutamate, N-linked glutamine, N-linked glycine, N-linked proline, N-linked serine, N-linked tyrosine, N-linked arginine, N-linked histidine, N-linked isoleucine, N-linked leucine, N-linked lysine, N-linked methionine, N-linked phenylalanine, N-linked threonine, N-linked tryptophan and N-linked valine, or an optionally substituted N-linked α-amino acid ester derivative, wherein the optionally substituted N-linked α-amino acid ester derivative is an unsubstituted C_{1-6} alkyl ester, an optionally substituted C_{3-6} cycloalkyl ester, an optionally substituted C_6 aryl ester, an optionally substituted C_{10} aryl ester or an optionally substituted benzyl ester of an N-linked α–amino acid selected from the group consisting of N-linked alanine, N-linked asparagine, N-linked aspartate, N-linked cysteine, N-linked glutamate, N-linked glutamine, N-linked glycine, N-linked proline, N-linked serine, N-linked tyrosine, N-linked arginine, N-linked histidine, N-linked isoleucine, N-linked leucine, N-linked lysine, N-linked methionine, N-linked phenylalanine, N-linked threonine, N-linked tryptophan and N-linked valine;

R^{10A} and R^{11A} are independently an optionally substituted N-linked α-amino acid selected from the group consisting of N-linked alanine, N-linked asparagine, N-linked aspartate, N-linked cysteine, N-linked glutamate, N-linked glutamine, N-linked glycine, N-linked proline, N-linked serine, N-linked tyrosine, N-linked arginine, N-linked histidine, N-linked isoleucine, N-linked leucine, N-linked lysine, N-linked methionine, N-linked phenylalanine, N-linked threonine, N-linked tryptophan and N-linked valine, or an optionally substituted N-linked α-amino acid ester derivative, wherein the optionally substituted N-linked α-amino acid ester derivative is an

unsubstituted C_{1-6} alkyl ester, an optionally substituted C_{3-6} cycloalkyl ester, an optionally substituted C_6 aryl ester, an optionally substituted C_{10} aryl ester or an optionally substituted benzyl ester of an N-linked α–amino acid selected from the group consisting of N-linked alanine, N-linked asparagine, N-linked aspartate, N-linked cysteine, N-linked glutamate, N-linked glutamine, N-linked glycine, N-linked proline, N-linked serine, N-linked tyrosine, N-linked arginine, N-linked histidine, N-linked isoleucine, N-linked leucine, N-linked lysine, N-linked methionine, N-linked phenylalanine, N-linked threonine, N-linked tryptophan and N-linked valine;

R^{12A} and R^{13A} are independently absent or hydrogen;

R^{14A} is O^- or OH;

R^{22A} and R^{23A} are each hydrogen;

R^{24A} is selected from the group consisting of hydrogen, an optionally substituted C_{1-24} alkyl and an optionally substituted –O–C_{1-24} alkyl;

m is 0 or 1;

s is 0, 1, 2 or 3; and

Z^{1A}, Z^{2A}, Z^{3A} and Z^{4A} are each O;

wherein the viral infection is caused by a virus selected from the group consisting of MERS-CoV, SARS-CoV, Venezuelan equine encephalitis virus, Chikungunya virus and a coronavirus; and

when a group is substituted, the group is substituted with one or more substituents selected from the group consisting of alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, heteroaryl, heterocyclyl, aryl(alkyl), heteroaryl(alkyl), (heterocyclyl)alkyl, hydroxy, alkoxy, acyl, cyano, halogen, thiocarbonyl, O-carbamyl, N-carbamyl, O-thiocarbamyl, N-thiocarbamyl, C-amido, N-amido, S-sulfonamido, N-sulfonamido, C-carboxy, O-carboxy, isocyanato, thiocyanato, isothiocyanato, nitro, azido, silyl, sulfenyl, sulfinyl, sulfonyl, haloalkyl, haloalkoxy, trihalomethanesulfonyl, trihalomethanesulfonamido, an amino, a mono-substituted amino group and a di-substituted amino group.

2. The use of Claim 1, wherein the virus is MERS-CoV.

3. The use of Claim 1, wherein the virus is SARS-CoV.

4. The use of Claim 1, wherein the virus is a Venezuelan equine encephalitis virus.

5. The use of Claim 1, wherein the virus is Chikungunya virus

6. The use of Claim 1, wherein the virus is a coronavirus.

7. The use of any one of Claims 1-6, wherein R^{2A} is halo.

8. The use of Claim 7, wherein the halo is fluoro.

9. The use of any one of Claims 1-6, wherein R^{2A} is $-(CH_2)_{1-6}$ halogen.

10. The use of Claim 9, wherein R^{2A} is $-(CH_2)_{1-6}F$.

11. The use of any one of Claims 1-10, wherein R^{4A} is OH.


12. The use of any one of Claims 1-10, wherein R^{4A} is halo.


13. The use of Claim 12, wherein the halo is F.


14. The use of any one of Claims 1-13, wherein R^{5A} is an unsubstituted C_{1-6} alkyl.

15. The use of any one of Claims 1-13, wherein R^{5A} is an unsubstituted C_{2-6} alkynyl.


16. The use of any one of Claims 1-15, wherein R^{1A} is hydrogen.

17. The use of any one of Claims 1-15, wherein R^{1A} is .


18. The use of Claim 17, wherein R^{6A} is , R^{7A} is absent or hydrogen; and m is 0.

19. The use of Claim 17, wherein R^{6A} is , R^{7A} is absent or hydrogen; and m is 1.

20. The use of Claim 17, wherein R^{6A} and R^{7A} are independently absent or hydrogen.

21. The use of Claim 17, wherein R^{6A} and R^{7A} are independently .

22. The use of Claim 17, wherein R^{6A} and R^{7A} are each isopropyloxycarbonyloxymethyl.

23. The use of any one of Claims 1-15, wherein R^{1A} is  .








24. The use of Claim 23, wherein R^{8A} is an optionally substituted phenyl.


25. The use of Claim 24, wherein R^{8A} is an unsubstituted phenyl.

26. The use of Claim 23, wherein R^{8A} is an optionally substituted naphthyl.

27. The use of any one of Claims 23-26, wherein R^{9A} is an optionally substituted N-linked amino acid selected from the group consisting of N-linked alanine, N-linked asparagine, N-linked aspartate, N-linked cysteine, N-linked glutamate, N-linked glutamine, N-linked glycine, N-linked proline, N-linked serine, N-linked tyrosine, N-linked arginine, N-linked histidine, N-linked isoleucine, N-linked leucine, N-linked lysine, N-linked methionine, N-linked phenylalanine, N-linked threonine, N-linked tryptophan and N-linked valine, or an optionally substituted N-linked amino acid ester derivative, wherein the optionally substituted N-linked α-amino acid ester derivative is an unsubstituted C_{1-6} alkyl ester, an optionally substituted C_{3-6} cycloalkyl ester, an optionally substituted C_6 aryl ester, an optionally substituted C_{10} aryl ester or an optionally substituted benzyl ester of an N-linked α–amino acid selected from the group consisting of N-linked alanine, N-linked asparagine, N-linked aspartate, N-linked cysteine, N-linked glutamate, N-linked glutamine, N-linked glycine, N-linked proline, N-linked serine, N-linked tyrosine, N-linked arginine, N-linked histidine, N-linked isoleucine, N-linked leucine, N-linked lysine, N-linked methionine, N-linked phenylalanine, N-linked threonine, N-linked tryptophan and N-linked valine.

28. The use of any one of Claims 23-26, wherein R^{9A} is an unsubstituted C_{1-6} alkyl ester or an unsubstituted C_{3-6} cycloalkyl ester of an N-linked α–amino acid selected from the group consisting of N-linked alanine, N-linked isoleucine, N-linked leucine and N-linked valine.








29. The use of Claim 27, wherein R^{9A} is selected from the group consisting of , , , , ,  and .



30. The use of any one of Claims 1-15, wherein R^{1A} is .

31. The use of Claim 30, wherein R^{10A} and R^{11A} are independently an optionally substituted N-linked amino acid selected from the group consisting of N-linked alanine, N-linked asparagine, N-linked aspartate, N-linked cysteine, N-linked glutamate, N-linked glutamine, N-linked glycine, N-linked proline, N-linked serine, N-linked tyrosine, N-linked arginine, N-linked histidine, N-linked isoleucine, N-linked leucine, N-linked lysine, N-linked methionine, N-linked phenylalanine, N-linked threonine, N-linked tryptophan and N-linked valine, or an optionally substituted N-linked amino acid ester derivative, wherein the optionally substituted N-linked α-amino acid ester derivative is an unsubstituted C_{1-6} alkyl ester, an optionally substituted C_{3-6} cycloalkyl ester, an optionally substituted C_6 aryl ester, an optionally substituted C_{10} aryl ester or an optionally substituted benzyl ester of an N-linked α–amino acid selected from the group consisting of N-linked alanine, N-linked asparagine, N-linked aspartate, N-linked cysteine, N-linked glutamate, N-linked glutamine, N-linked glycine, N-linked proline, N-linked serine, N-linked tyrosine, N-linked arginine, N-linked histidine, N-linked isoleucine, N-linked leucine, N-linked lysine, N-linked methionine, N-linked phenylalanine, N-linked threonine, N-linked tryptophan and N-linked valine.

32. The use of Claim 30, wherein R^{10A} and R^{11A} are independently an unsubstituted C_{1-6} alkyl ester or an unsubstituted C_{3-6} cycloalkyl ester of an N-linked α–amino acid selected from the group consisting of N-linked alanine, N-linked isoleucine, N-linked leucine and N-linked valine.

33. The use of Claim 31, wherein R^{10A} and R^{11A} are independently selected from the group consisting of , , , , ,  and .


34. The use of any one of Claims 1-33, wherein R^{3A} is halo.



35. The use of Claim 34, wherein the halo is fluoro.

36. The use of any one of Claims 1-35, wherein R^{3A} is OH.

37. The use of any one of Claims 1-36, wherein R^{A} is hydrogen.

38. The use of any one of Claims 1-37, wherein R^{a1} and R^{a2} are both hydrogen.

39. The use of any one of Claims 1-38, wherein B^{1A} is .

40. The use of any one of Claims 1-38, wherein B^{1A} is , , wherein R^{G2} is $–CH_2CH_3$.

41. The use of any one of Claims 1-6, wherein:




























R^{2A} is selected from the group consisting of hydrogen, F and $–CH_2F$;

R^{3A} is OH or F;

R^{4A} is selected from the group consisting of OH, Cl and F; and









R^{5A} is methyl or ethynyl.

42. The use of any one of Claims 1-6, wherein the compound of Formula (I) is selected from the group consisting of:


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

and





, or a pharmaceutically acceptable salt of any of the foregoing.











43. The use of any one of Claims 1-6, wherein the compound is selected from the group consisting of:



,

,

,

,

,

,

and

,











or a pharmaceutically acceptable salt of any of the foregoing.


44. The use of any one of Claims 1-6, wherein the compound is selected from the group consisting of:


,

,

,

,










,

,

,

,

,

,

,

,

,

,



,

,


,

,

,

,

,

,

,

,

,

and



, or a pharmaceutically acceptable salt of any of the foregoing.


45. The use of any one of Claims 1-6, wherein the compound is selected from the group consisting of:


,

,

,

,

,

,

,

,



 and ,



or a pharmaceutically acceptable salt of any of the foregoing.



46. The use of any one of Claims 1-6, wherein the compound of Formula (I) is , or a pharmaceutically acceptable salt thereof.



47. The use of Claim 46, wherein B^{1A} is , wherein R^{G2} is $-CH_2CH_3$.



48. The use of Claim 46, wherein R^{1A} is H.


49. The use of Claim 46, wherein R^{1A} is ; R^{6A} is ; R^{7A}, R^{12A} and R^{13A} are independently absent or hydrogen; m is 1; and R^{14A} is O^- or OH.


50. The use of Claim 46, wherein R^{1A} is , R^{6A} and R^{7A} are each ; s is 0; R^{22A} and R^{23A} are each hydrogen; and R^{24A} is an unsubstituted tert-butyl.

51. The use of Claim 46, wherein R^{1A} is , R^{6A} and R^{7A} are each ; s is 0; R^{22A} and R^{23A} are each hydrogen; and R^{24A} is an unsubstituted O-isopropyl.



52. The use of Claim 46, wherein R^{1A} is , R^{8A} is an unsubstituted phenyl; and R^{9A} is .



53. The use of Claim 46, wherein R^{1A} is , R^{8A} is an unsubstituted phenyl; and R^{9A} is .



54. The use of any one of Claims 1-6, wherein the compound of Formula (I) is , or a pharmaceutically acceptable salt thereof.



55. The use of Claim 54, wherein B^{1A} is , wherein R^{G2} is -CH_2CH_3.



56. The use of Claim 54, wherein R^{1A} is H.


57. The use of Claim 54, wherein R^{1A} is ; R^{6A} is ; R^{7A}, R^{12A} and R^{13A} are independently absent or hydrogen; m is 1; and R^{14A} is O^- or OH.


58. The use of Claim 54, wherein R^{1A} is , R^{6A} and R^{7A} are each ; s is 0; R^{22A} and R^{23A} are each hydrogen; and R^{24A} is an unsubstituted tert-butyl.

59. The use of Claim 54, wherein R^{1A} is , R^{6A} and R^{7A} are each ; s is 0; R^{22A} and R^{23A} are each hydrogen; and R^{24A} is an unsubstituted O-isopropyl.



60. The use of Claim 54, wherein R^{1A} is , R^{8A} is an unsubstituted phenyl; and R^{9A} is .



61. The use of Claim 54, wherein R^{1A} is , R^{8A} is an unsubstituted phenyl; and R^{9A} is .



62. The use of any one of Claims 1-6, wherein the compound of Formula (I) is , or a pharmaceutically acceptable salt thereof.



63. The use of Claim 62, wherein B^{1A} is , wherein R^{G2} is -CH_2CH_3.



64. The use of Claim 62, wherein R^{1A} is H.


65. The use of Claim 62, wherein R^{1A} is ; R^{6A} is ; R^{7A}, R^{12A} and R^{13A} are independently absent or hydrogen; m is 1; and R^{14A} is O^- or OH.


66. The use of Claim 62, wherein R^{1A} is , R^{6A} and R^{7A} are each ; s is 0; R^{22A} and R^{23A} are each hydrogen; and R^{24A} is an unsubstituted tert-butyl.

67. The use of Claim 62, wherein R^{1A} is , R^{6A} and R^{7A} are each ; s is 0; R^{22A} and R^{23A} are each hydrogen; and R^{24A} is an unsubstituted O-isopropyl.



68. The use of Claim 62, wherein R^{1A} is , R^{8A} is an unsubstituted phenyl; and R^{9A} is .



69. The use of Claim 62, wherein R^{1A} is , R^{8A} is an unsubstituted phenyl; and R^{9A} is .



70. The use of any one of Claims 1-6, wherein the compound of Formula (I) is , or a pharmaceutically acceptable salt thereof.



71. The use of Claim 70, wherein B^{1A} is , wherein R^{G2} is -CH_2CH_3.



72. The use of Claim 70, wherein R^{1A} is H.



73. The use of Claim 70, wherein R^{1A} is ; R^{6A} is ; R^{7A}, R^{12A} and R^{13A} are independently absent or hydrogen; m is 1; and R^{14A} is O^- or OH.



74. The use of Claim 70, wherein R^{1A} is , R^{6A} and R^{7A} are each ; s is 0; R^{22A} and R^{23A} are each hydrogen; and R^{24A} is an unsubstituted tert-butyl.



75. The use of Claim 70, wherein R^{1A} is , R^{6A} and R^{7A} are each ; s is 0; R^{22A} and R^{23A} are each hydrogen; and R^{24A} is an unsubstituted O-isopropyl.



76. The use of Claim 70, wherein R^{1A} is , R^{8A} is an unsubstituted phenyl; and R^{9A} is .


77. The use of Claim 70, wherein R^{1A} is , R^{8A} is an unsubstituted phenyl; and R^{9A} is .


78. The use of any one of Claims 1-6, wherein the compound is , or a pharmaceutically acceptable salt thereof, wherein B^{1A} is ; R^{G2} is $-CH_2CH_3$; and R^{1A} is hydrogen.

79. The use of any one of Claims 1-6, wherein the compound is , or a pharmaceutically acceptable salt thereof, wherein B^{1A} is ; R^{G2} is $-CH_2CH_3$; and R^{1A} is hydrogen.


80. The use of any one of Claims 1-6, wherein the compound is , or a pharmaceutically acceptable salt thereof, wherein B^{1A} is ; R^{G2} is $-CH_2CH_3$; and R^{1A} is hydrogen.

81. The use of any one of Claims 1-6, wherein the compound is , or a pharmaceutically acceptable salt thereof, wherein B^{1A} is ; R^{G2} is $-CH_2CH_3$; and R^{1A} is hydrogen.

82. The use of any one of Claims 1-6, wherein the compound is , or a pharmaceutically acceptable salt thereof.


83. The use of any one of Claims 1-6, wherein the compound is , or a pharmaceutically acceptable salt thereof.

84. The use of any one of Claims 1-6, wherein the compound is




, or a pharmaceutically acceptable salt thereof.

85. The use of any one of Claims 1-6, wherein the compound is




, or a pharmaceutically acceptable salt thereof.

86. The use of any one of Claims 1-6, wherein the compound is




, or a pharmaceutically acceptable salt thereof.

87. The use of any one of Claims 1-6, wherein the compound is




, or a pharmaceutically acceptable salt thereof.

88. The use of Claim 87, wherein the compound is




, or a pharmaceutically acceptable salt thereof.

89. The use of Claim 88, wherein the compound is




, or a pharmaceutically acceptable salt thereof.

90. The use of any one of Claims 1-6, wherein the compound is




, or a pharmaceutically acceptable salt thereof.

91. The use of any one of Claims 1-6, wherein the compound is




, or a pharmaceutically acceptable salt thereof.

92. The use of any one of Claims 1-6, wherein the compound is




, or a pharmaceutically acceptable salt thereof.

93. The use of any one of Claims 1-6, wherein the compound is




, or a pharmaceutically acceptable salt thereof.

94. The use of any one of Claims 1-6, wherein the compound is




, or a pharmaceutically acceptable salt thereof.

95. The use of any one of Claims 1-6, wherein the compound is




, or a pharmaceutically acceptable salt thereof.

96. The use of any one of Claims 1-6, wherein the compound is



, or a pharmaceutically acceptable salt thereof.

97. The use of any one of Claims 1-6, wherein the compound is



, or a pharmaceutically acceptable salt thereof.